| AChR | Acetylcholine receptor |
| AChR-Ab+ | Acetylcholine receptor antibody-positive |
| AMSTAR 2 | A Measurement Tool to Assess Systematic Reviews 2 |
| C5 | Complement component 5 |
| CCA | Corrected covered area |
| FcRn | Neonatal Fc receptor |
| FDA | U.S. Food and Drug Administration |
| gMG | Generalized myasthenia gravis |
| GROOVE | Graphical Representation of Overlap for Overviews |
| IgG | Immunoglobulin G |
| ITC | Indirect treatment comparison |
| JBI | Joanna Briggs Institute |
| LRP4 | Low-density lipoprotein receptor-related protein 4 |
| MeSH | Medical Subject Headings |
| MG | Myasthenia gravis |
| MG-ADL | Myasthenia Gravis Activities of Daily Living |
| MGC | Myasthenia Gravis Composite |
| MGFA | Myasthenia Gravis Foundation of America |
| MGFA-PIS | Myasthenia Gravis Foundation of America Post-Intervention Status |
| MG-QOL15r | 15-item revised Myasthenia Gravis Quality of Life scale |
| MuSK | Muscle-specific kinase |
| NMA | Network meta-analysis |
| OSF | Open Science Framework |
| PICO | Population, Intervention, Comparator, and Outcome |
| PRISMA | Preferred Reporting Items for Systematic Reviews and Meta-Analyses |
| QMG | Quantitative Myasthenia Gravis |
| RCT | Randomized controlled trial |
| RTX | Rituximab |
| SR | Systematic review |